Company overview
Axol Bioscience specializes in high-quality induced pluripotent stem cell (iPSC) products and services to support drug discovery and R&D. Key offerings include axoLines™ (over 70 characterized iPSC lines), axoCells™ (functional iPSC-derived cells like neurons and cardiomyocytes), axoServices™ (custom lab services), and axoModels™ (collaborative iPSC-based models). The company focuses on neurodegenerative diseases, peripheral nervous system disorders, and cardiotoxicity, with manufacturing under ISO 9001 at sites in the UK.
Axol Bioscience is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include ipsc derived cells, axol bioscience, stem cell lines, neurons supplier, cardiomyocytes.
Structured facts
- Website
- https://axolbioscience.com
- Markets served
- United States & Americas
- Keywords
- ipsc derived cells, axol bioscience, stem cell lines, neurons supplier, cardiomyocytes
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What iPSC-derived cell types does Axol Bioscience offer?
- Axol provides high-quality axoCells™ including neuronal cells (astrocytes, cortical excitatory neurons, microglia), sensory neurons for pain and touch, and chamber-specific cardiomyocytes (atrial and ventricular) for cardiotoxicity studies.
- What regulatory standards does Axol Bioscience follow?
- Manufacturing occurs at scale under ISO 9001 guidelines at the Roslin Innovation Centre in the UK, ensuring quality and consistency for iPSC products.
- Where are Axol Bioscience's facilities located?
- Axol operates two main UK sites: a manufacturing facility at Roslin Innovation Centre in Easter Bush and an R&D hub at Babraham Research Campus in Cambridge, serving customers globally.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
